Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
Restricted accessResearch articleFirst published online August, 2002
Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis
The efficacy of glatiramer acetate in multiple sclerosis (MS) is thought to involve the production of Th2 regulatory lymphocytes that secrete anti-inflammatory cytokines; however, other mechanisms cannot be excluded. Given that activated T lymphocytes infiltrate into the CNS and become in close proximity to microglia, we evaluated whether glatiramer acetate affects the potential interaction between T cells and microglia. We report that the co-culture of activated T lymphocytes with microglia led to the induction of several cytokines, and that these were reduced by glatiramer acetate treatment. Morphological transformation of bipolar/ramified microglia into an activated ameboid form was attenuated by glatiramer acetate. These results reveal a novel mechanism for glatiramer acetate: the impairment of activated T cells to effectively interact with microglia to produce cytokines. The net result of a non-inflammatory milieu within the CNS, in spite of T cell infiltration, may help account for the amelioration of disease activity in MS patients on glatiramer acetate therapy.
Bornstein MB , Miller A , Slagle S , et al.A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis . N Engl J Med1987; 317: 408-414 .
2.
Johnson KP , Brooks BR , Cohen JA , et al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology1995; 45: 1268-1276 .
3.
Johnson KP , Brooks BR , Ford CC , et al.Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years . Mult Scler2000; 6: 255-266 .
4.
Wolinsky JS , Narayana PA , Johnson KP and the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center . United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates . Mult Scler2001; 7: 33-41 .
5.
Ben-Nun A , Mendel I , Bakimer R , et al.The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease . J Neurol1996; 243: S14-S22 .
6.
Teitelbaum D , Fridkis-Hareli M , Arnon R , Sela M.Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses . J Neuroimmunol1996; 64: 209-217 .
7.
Teitelbaum D , Arnon R , Sela M.Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1 . Proc Natl Acad Sci USA1999; 96: 3842-3847 .
8.
Neuhaus O , Farina C , Yassouridis A , et al.Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells . Proc Natl Acad Sci USA2000; 97: 7452-7457 .
9.
Sela M , Teitelbaum D.Glatiramer acetate in the treatment of multiple sclerosis . Exp Opin Pharmacother2001; 2: 1149-1165 .
10.
Teitelbaum D , Milo R , Arnon R , Sela M.Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein . Proc Natl Acad Sci USA1992; 89: 137-141 .
11.
Racke MK , Martin R , McFarland H , Fritz RB.Copolymer- 1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation . J Neuroimmunol1992; 37: 75-84 .
12.
Arnon R , Sela M , Teitelbaum D.New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis . J Neurol1996; 243: S8-S13 .
13.
Fridkis-Hareli M , Strominger JL.Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules . J Immunol1998; 160: 4386-4397 .
14.
Aharoni R , Teitelbaum D , Sela M , Arnon R.Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 . J Neuroimmunol1998; 90: 135-146 .
15.
Duda PW , Schmied MC , Cook SL , Krieger JI , Hafler OA.Glatiramer acetate (Copaxone®) induces degenerate Th2-polarized immune responses in patients with multiple sclerosis . J Clin Invest2000; 105: 967-976 .
16.
Aharoni R , Teitelbaum D , Arnon R , Sela M.Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatiblity complex blocking . Proc Natl Acad Sci USA1999; 96: 634-639 .
17.
Aharoni R , Teitelbaum D , Arnon RT.Suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis . Eur J Immunol1993; 23: 17-25 .
18.
Aharoni R , Teitelbaum D , Sela M , Arnon R.Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis . Proc Natl Acad Sci USA1997; 94: 10821-10826 .
19.
Miller A , Shapiro S , Gershtein R , et al.Treatment of multiple sclerosis with copolymer-1 (copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation . J Neuroimmunol1998; 92: 113-121 .
20.
Neuhaus O , Farina C , Wekerle H , Hohlfeld R.Mechanisms of action of glatiramer acetate in multiple sclerosis . Neurology2001; 56: 702-708 .
21.
Qin Y , Zhang DQ , Prat A , Pouly S , Antei J.Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients . J Neuroimmunol2000; 108: 201-206 .
22.
Gran B , Tranquill LR , Chen M , Bickkova B.Mechanisms of immunomodulation by glatiramer acetate . Neurology2000; 55: 1704-1714 .
23.
Farina C , Then Bergh F , Albrecht H , et al.Treatment of multiple sclerosis with copaxone (Cop) Elispot assay detects COP-induced interleukin-4 and interferon-g response in blood cells . Brain2001; 124: 705-719 .
24.
Chabot S , Williams G , Yong VW.Microglial production TNF-a is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferon b-1b . J Clin Invest1997; 100: 604-612 .
25.
Chabot S , Williams G , Hamilton M , Sutherland G , Yong VW.Mechanisms of IL-10 production in human microglia -T cell interaction . J Immunol1999; 162: 6819-6828 .
26.
Chabot S , Yong VW.Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS . Neurol2000; 55: 1497-1505 .
27.
Louis J-C , Magal E , Takayama S , Varon S.CNTF protection of oligodendrocytes against natural and tumor necrosis factor a-induced death . Science1993; 259: 689-692 .
28.
Loughlin AJ , Honegger P , Woodroofe MN , Comte V , Matthieu JM , Cuzner ML.Myelin basic protein content of aggregating rat brain cell cultures treated with cytokines and/or demyelinating antibody: effects of macrophage enrichment . J Neurosci Res1994; 37: 647-653 .
29.
Yong VW , Chabot S , Stuve O , Williams G.Interferon beta in the treatment of multiple sclerosis: mechanisms of action . Neurology1998; 51: 682-689 .
30.
Lee SC , Liu W , Brosnan CF , Dickson DW.Characterization of primary human fetal dissociated central nervous system cultures with an emphasis on microglia . Lab Invest1992; 67: 465-476 .
31.
Chabot S , Charlet D , Wilson TL , Yong VW.Cytokine production in T cell-microglia interaction: the PMA/IFNg -treated U937 monocytoid cells as a model of human adult microglia . J Neurosci Methods2001; 105: 111-120 .
32.
Bohnsack JF , Akiyama SK , Damsky CH , Knape WA , Zimmerman GA.Human neutrophil adherence to laminin in vitro. Evidence for a distinct neutropil integrin receptor for laminin . J Exp Med1990; 171: 1221-1237 .
33.
Wiesemann E , Klatt J , Sonmez D , Blasczyk R , Heidenreich F , Windragen A.Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naïve T cells . J Neuroimmunol2001; 119: 137-144 .
34.
Hohlfeld R.Biotechnological agents for the immunotheraphy of multiple sclerosis: principles, problems, and perspectives . Brain1997; 120: 865-916 .
35.
Schrijver HM , Crusius JB , Uitdehaag BM , et al.Association of interleukin-1b and interleukin-1 receptor antagonist genes with disease severity in MS . Ann Neurol1999; 52: 95-599 .
36.
Bo L , Mork S , Kong PA , Nyland H , Pardo CA , Trapp BD.Detection of MHC class II antigens on macrophages and microglia but not on astrocytes and endothelia in active multiple sclerosis lesions . J Neuroimmunol1994; 51: 135-146 .
37.
Noseworthy JH , Lucchinetti C , Rodriguez M , Weinshenker BG.Multiple sclerosis . N Engl J Med2000; 343: 938-952 .
38.
Aharoni R , Teitelbaun D , Leither O , Meshorer A , Sela M , Aaron R.Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1 . Proc Natl Acad Sci USA2000; 971: 1472-11477 .
39.
Sedgwick J , Brostoff S , Mason D.Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction: severe paralytic disease correlates with the presence of interleukin-2 receptor-positive cells infiltrating the central nervous system . J Exp Med1987; 165: 1058-1075 .
40.
Cross AH , O’Mara T , Raine CS.Chronologic localization of myelin-reactive cells in the lesions of relapsing EAE . Neurology1993; 43: 1028-1033 .
41.
Raivich G , Jones LL , Kloss CU , Werner A , Neumann H , Kreutzberg GW.Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomised mouse facial motor nucleus and aggregate around sites of neuronal degeneration . J Neurosci1998; 18: 5804-5818 .
42.
Sedgwick JD , Ford AL , Foulcher E , Airriess R.Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts . J Immunol1998; 160: 5320-5330 .
Dufour A , Corsini E , Gelati M , Massa G , Tarcic N , Salmaggi A.In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena . Ann Neurol2000; 47: 680-682 .
45.
Lobel E , Riven-Kreitman R , Amselem A , Pinchasi I.Copolymer- 1 . Drugs Future1996; 21: 131-134 .
